Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin

Detalhes bibliográficos
Autor(a) principal: Danilovic, Debora Lucia Seguro
Data de Publicação: 2011
Outros Autores: Mendes-Correa, Maria Cassia, Chammas, Maria Cristina, Zambrini, Heverton, Marui, Suemi
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/19489
Resumo: OBJECTIVE: To characterize thyroid disturbances induced by interferon-alpha and ribavirin therapy in patients with chronic hepatitis C. INTRODUCTION: Interferon-alpha is used to treat chronic hepatitis C infections. This compound commonly induces both autoimmune and non-autoimmune thyroiditis. METHODS: We prospectively selected 26 patients with chronic hepatitis C infections. Clinical examinations, hormonal evaluations, and color-flow Doppler ultrasonography of the thyroid were performed before and during antiviral therapy. RESULTS: Of the patients in our study, 54% had no thyroid disorders associated with the interferon-alpha therapy but showed reduced levels of total T3 along with a decrease in serum alanine aminotransferase. Total T4 levels were also reduced at 3 and 12 months, but free T4 and thyroid stimulating hormone (TSH) levels remained stable. A total of 19% of the subjects had autoimmune interferon-induced thyroiditis, which is characterized by an emerge of antithyroid antibodies or overt hypothyroidism. Additionally, 16% had non-autoimmune thyroiditis, which presents as destructive thyroiditis or subclinical hypothyroidism, and 11% remained in a state of euthyroidism despite the prior existence of antithyroidal antibodies. Thyrotoxicosis with destructive thyroiditis was diagnosed within three months of therapy, and ultrasonography of these patients revealed thyroid shrinkage and discordant change in the vascular patterns. DISCUSSION: Decreases in the total T3 and total T4 levels may be related to improvements in the hepatocellular lesions or inflammatory changes similar to those associated with nonthyroidal illnesses. The immune mechanisms and direct effects of interferon-alpha can be associated with thyroiditis. CONCLUSION: Interferon-alpha and ribavirin induce autoimmune and non-autoimmune thyroiditis and hormonal changes (such as decreased total T3 and total T4 levels), which occur despite stable free T4 and TSH levels. A thyroid hormonal evaluation, including the analysis of the free T4, TSH, and antithyroid antibody levels, should be mandatory before therapy, and an early re-evaluation within three months of treatment is necessary as an appropriate follow-up.
id USP-19_1fddb0faa3270ead7df1f498754b1a43
oai_identifier_str oai:revistas.usp.br:article/19489
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin Thyroid hormonesHepatitis CInterferon-induced thyroiditisDestructive thyroiditisThyroid ultrasonography OBJECTIVE: To characterize thyroid disturbances induced by interferon-alpha and ribavirin therapy in patients with chronic hepatitis C. INTRODUCTION: Interferon-alpha is used to treat chronic hepatitis C infections. This compound commonly induces both autoimmune and non-autoimmune thyroiditis. METHODS: We prospectively selected 26 patients with chronic hepatitis C infections. Clinical examinations, hormonal evaluations, and color-flow Doppler ultrasonography of the thyroid were performed before and during antiviral therapy. RESULTS: Of the patients in our study, 54% had no thyroid disorders associated with the interferon-alpha therapy but showed reduced levels of total T3 along with a decrease in serum alanine aminotransferase. Total T4 levels were also reduced at 3 and 12 months, but free T4 and thyroid stimulating hormone (TSH) levels remained stable. A total of 19% of the subjects had autoimmune interferon-induced thyroiditis, which is characterized by an emerge of antithyroid antibodies or overt hypothyroidism. Additionally, 16% had non-autoimmune thyroiditis, which presents as destructive thyroiditis or subclinical hypothyroidism, and 11% remained in a state of euthyroidism despite the prior existence of antithyroidal antibodies. Thyrotoxicosis with destructive thyroiditis was diagnosed within three months of therapy, and ultrasonography of these patients revealed thyroid shrinkage and discordant change in the vascular patterns. DISCUSSION: Decreases in the total T3 and total T4 levels may be related to improvements in the hepatocellular lesions or inflammatory changes similar to those associated with nonthyroidal illnesses. The immune mechanisms and direct effects of interferon-alpha can be associated with thyroiditis. CONCLUSION: Interferon-alpha and ribavirin induce autoimmune and non-autoimmune thyroiditis and hormonal changes (such as decreased total T3 and total T4 levels), which occur despite stable free T4 and TSH levels. A thyroid hormonal evaluation, including the analysis of the free T4, TSH, and antithyroid antibody levels, should be mandatory before therapy, and an early re-evaluation within three months of treatment is necessary as an appropriate follow-up. Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2011-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/1948910.1590/S1807-59322011001000014Clinics; Vol. 66 No. 10 (2011); 1757-1763 Clinics; v. 66 n. 10 (2011); 1757-1763 Clinics; Vol. 66 Núm. 10 (2011); 1757-1763 1980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/19489/21552Danilovic, Debora Lucia SeguroMendes-Correa, Maria CassiaChammas, Maria CristinaZambrini, HevertonMarui, Suemiinfo:eu-repo/semantics/openAccess2012-05-23T16:43:36Zoai:revistas.usp.br:article/19489Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2012-05-23T16:43:36Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin
title Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin
spellingShingle Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin
Danilovic, Debora Lucia Seguro
Thyroid hormones
Hepatitis C
Interferon-induced thyroiditis
Destructive thyroiditis
Thyroid ultrasonography
title_short Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin
title_full Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin
title_fullStr Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin
title_full_unstemmed Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin
title_sort Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin
author Danilovic, Debora Lucia Seguro
author_facet Danilovic, Debora Lucia Seguro
Mendes-Correa, Maria Cassia
Chammas, Maria Cristina
Zambrini, Heverton
Marui, Suemi
author_role author
author2 Mendes-Correa, Maria Cassia
Chammas, Maria Cristina
Zambrini, Heverton
Marui, Suemi
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Danilovic, Debora Lucia Seguro
Mendes-Correa, Maria Cassia
Chammas, Maria Cristina
Zambrini, Heverton
Marui, Suemi
dc.subject.por.fl_str_mv Thyroid hormones
Hepatitis C
Interferon-induced thyroiditis
Destructive thyroiditis
Thyroid ultrasonography
topic Thyroid hormones
Hepatitis C
Interferon-induced thyroiditis
Destructive thyroiditis
Thyroid ultrasonography
description OBJECTIVE: To characterize thyroid disturbances induced by interferon-alpha and ribavirin therapy in patients with chronic hepatitis C. INTRODUCTION: Interferon-alpha is used to treat chronic hepatitis C infections. This compound commonly induces both autoimmune and non-autoimmune thyroiditis. METHODS: We prospectively selected 26 patients with chronic hepatitis C infections. Clinical examinations, hormonal evaluations, and color-flow Doppler ultrasonography of the thyroid were performed before and during antiviral therapy. RESULTS: Of the patients in our study, 54% had no thyroid disorders associated with the interferon-alpha therapy but showed reduced levels of total T3 along with a decrease in serum alanine aminotransferase. Total T4 levels were also reduced at 3 and 12 months, but free T4 and thyroid stimulating hormone (TSH) levels remained stable. A total of 19% of the subjects had autoimmune interferon-induced thyroiditis, which is characterized by an emerge of antithyroid antibodies or overt hypothyroidism. Additionally, 16% had non-autoimmune thyroiditis, which presents as destructive thyroiditis or subclinical hypothyroidism, and 11% remained in a state of euthyroidism despite the prior existence of antithyroidal antibodies. Thyrotoxicosis with destructive thyroiditis was diagnosed within three months of therapy, and ultrasonography of these patients revealed thyroid shrinkage and discordant change in the vascular patterns. DISCUSSION: Decreases in the total T3 and total T4 levels may be related to improvements in the hepatocellular lesions or inflammatory changes similar to those associated with nonthyroidal illnesses. The immune mechanisms and direct effects of interferon-alpha can be associated with thyroiditis. CONCLUSION: Interferon-alpha and ribavirin induce autoimmune and non-autoimmune thyroiditis and hormonal changes (such as decreased total T3 and total T4 levels), which occur despite stable free T4 and TSH levels. A thyroid hormonal evaluation, including the analysis of the free T4, TSH, and antithyroid antibody levels, should be mandatory before therapy, and an early re-evaluation within three months of treatment is necessary as an appropriate follow-up.
publishDate 2011
dc.date.none.fl_str_mv 2011-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/19489
10.1590/S1807-59322011001000014
url https://www.revistas.usp.br/clinics/article/view/19489
identifier_str_mv 10.1590/S1807-59322011001000014
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/19489/21552
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 66 No. 10 (2011); 1757-1763
Clinics; v. 66 n. 10 (2011); 1757-1763
Clinics; Vol. 66 Núm. 10 (2011); 1757-1763
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1800222757346082816